XEMPERIA, a spin-off from the University of Fribourg, is pioneering a groundbreaking approach to blood testing that leverages the body's immune response to detect breast cancer at its earliest and most treatable stage.
Products, services, technology
XEMPERIA's flagship product is a PCR kit for the early detection of breast cancer, featuring reagents, protocols, and software.
In addition, XEMPERIA is developing advanced nanosensors for nucleic acid detection, utilizing DNA-based nanotechnologies to incorporate into point of care (PoC) devices.
Cooperation possibilities
XEMPERIA welcomes collaboration with molecular diagnostic laboratories, leading diagnostic and pharmaceutical companies, diagnostic imaging firms, and healthcare providers to accelerate market entry and seamlessly integrate into the medical diagnostics landscape.
- https://xemperia.com
- Send an email
- Curzio Rüegg, CEO
Some insights
XEMPERIA is revolutionizing breast cancer screening with a groundbreaking blood test for early detection, aiming to reduce mortality and save lives. By enabling faster, more accessible diagnostics, we empower patients and healthcare providers, making the world a healthier and better place.
We are proud of our innovative blood test offering superior accuracy and accessibility compared to traditional methods, that will revolutionize breast cancer detection. Our commitment to cutting-edge research and early detection aims to save lives and shape a healthier future for all women.
We believe innovation in human health must be approached with responsibility, equity, transparency, and accountability. Among our role models are: Biogen's, Illumina's, and Genentech’s patient-centric ethical approaches, the Human Genome Project, the Gates Foundation, and Dr. Fauci’s advocacy.
Our core strengths lie in scientific expertise, innovative thinking, collaboration, and commitment to ethical vision. To ensure future success, we are you looking forward to integrate regulatory expertise, data science & AI, commercialization strategies, and global health access for scalable impact.
We are contributing to improve human health and medical care and make our world a better place.
The Swiss biotech ecosystem can support XEMPERIA by providing access to world-class collaborations, a strong regulatory environment, networking opportunities, industry events, access to venture capital, and collaborations & partnering with pharma and biotech companies.
To accelerate growth, XEMPERIA is interested in establishing contacts with regulatory bodies, pharma/diagnostic companies, venture capital, healthcare providers, CROs, patient advocacy groups, insurance providers, tech partners, and global health organizations.